IMMX — Immix Biopharma Income Statement
0.000.00%
Last trade - 00:00- $368.72m
- $352.78m
Annual income statement for Immix Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.454 | 1.44 | 8.22 | 16.1 | 22.7 |
| Operating Profit | -0.454 | -1.44 | -8.22 | -16.1 | -22.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.13 | -24.4 | -8.22 | -15.6 | -21.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.15 | -24.4 | -8.23 | -15.6 | -21.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.15 | -24.4 | -8.23 | -15.4 | -21.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.15 | -24.4 | -8.23 | -15.4 | -21.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.159 | -3.38 | -0.593 | -0.89 | -0.764 |